Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease.
Level V
Where this comes from
- Record sourced from PubMed, PMID 30665567.
- Also identified by DOI 10.1016/j.kint.2018.11.016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anti-phospholipase A2 receptor (PLA2R) antibody is a specific biomarker for primary membranous nephropathy (MN). Testing positive for anti-PLA2R has been postulated to establish a diagnosis of MN in the absence of a kidney biopsy. Bobart et al. tested this hypothesis and concluded that anti-PLA2R positivity is sufficient to diagnose primary MN and initiate treatment in a subset of patients with nephropathy. This biomarker, however, does not render the kidney biopsy obsolete, but encourages the application of molecular analyses to renal pathology to keep the biopsy relevant.
Medical subject headings
- Glomerulonephritis, Membranous
- Receptors, Phospholipase A2